PTC Therapeutics (PTCT) PT Cut To $40 At Barclays After Sizable Translarna Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
PTC Therapeutics (PTCT) PT Lowered to $46 at RBC Capital
November 6, 2018 6:46 AM ESTRBC Capital analyst Brian Abrahams lowered the price target on PTC Therapeutics (NASDAQ: PTCT) to $46.00 (from $51.00) while maintaining an Outperform rating.
"3Q optics were unfavorable, given the Translarna miss, Emflaza guidance adjustment, and increased spend, and we could see shares trade off modestly," Abrahams commented.
... More